Wu Jinzi, founder and chief executive of Hangzhou-based biotechnology company Ascletis Pharma. Photo: Handout
Wu Jinzi, founder and chief executive of Hangzhou-based biotechnology company Ascletis Pharma. Photo: Handout
IPO

Chinese biotech firm Ascletis first to apply for Hong Kong IPO under new rules

Hangzhou-based Ascletis says its close to launching the hepatitis C treatment Danoprevir by September 30

Wu Jinzi, founder and chief executive of Hangzhou-based biotechnology company Ascletis Pharma. Photo: Handout
Wu Jinzi, founder and chief executive of Hangzhou-based biotechnology company Ascletis Pharma. Photo: Handout
READ FULL ARTICLE